Complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy in patients scheduled to undergo radical cystectomy for muscle-invasive bladder is associated with improved overall and cancer-specific survival, a study found.
In current urological practice, clinicians decide whether to place a ureteral stent or nephrostomy, but evidence-based treatment guidance is needed.
Seminal vesicle-sparing radical cystectomy improved functional results over a median of 64 months without compromising oncologic outcomes, according to investigators.
Low adherence to post-radical cystectomy surveillance guidelines may increase patients’ mortality risk, study findings suggest.
Robot-assisted and open radical cystectomy are associated with similar 90-day complication rates, health-related quality of life, and clinical outcomes, according to a recent real-world study.
A single-institution study found no significant increase in the risk for complications or readmissions between patients who underwent robotic urologic surgery before and during the COVID-19 pandemic.
A study at Memorial Sloan Kettering Cancer Center found that the 5-year probability of dying from bladder cancer following radical cystectomy dropped from 35% to 25%.
In a small study of radical cystectomy patients, perioperative hypogonadism persisted up to 90 days after surgery.
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
Bladder preservation for MIBC is associated with a higher mortality rate and greater costs compared with radical cystectomy.
